Triglycerides, Medium Chain
Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency; and dietary management of conditions requiring a source of medium chain triglycerides (chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, fat malabsorption).
Decisions on record
The committee reached more than one outcome for this medicine at its most recent sitting — different indications were decided differently. The header reflects the least favourable of them; all are listed below.
- Meeting Jul 2025 Recommended Chylous ascites, chylothorax, fat malabsorption, hyperlipoproteinaemia type 1, intractable childhood epilepsy, cerebrospinal fluid glucose transporter defect, long chain fatty acid oxidation disorders no PSD
- Meeting Jul 2025 Withdrawn Chylous ascites, chylothorax, fat malabsorption, hyperlipoproteinaemia type 1, intractable childhood epilepsy, cerebrospinal fluid glucose transporter defect, long chain fatty acid oxidation disorders no PSD
- Meeting Mar 2022 Recommended Ketogenic diet
- Meeting Mar 2016 Recommended Medicinal food
- Meeting Nov 2015 Recommended Medicinal food
- Meeting Nov 2015 Deferred Medicinal food
- Meeting Nov 2013 Recommended formula oral liquid, 250 mL x 18 tetrapak BetaQuik® Vitaflo Australia Pty Ltd Minor submission Medicinal food Restricted benefit listing for: patients requiring a medium chain triglycerides (MCT) diet such as the ketogenic treatment of intractable childhood epilepsy, cerebrospinal fluid glucose tran no PSD
- Meeting Mar 2012 Recommended Medicinal food no PSD
4 earlier decisions
- Nov 2009 Recommended Medicinal food no PSD
- Jul 2009 Recommended Medicinal food no PSD
- Jul 2007 Recommended Food no PSD
- Sep 2002 Recommended A food for inborn errors of metabolism no PSD
Access path
- Mar 2022Recommended
vs Betaquik
- PBS listing · Authority Required
From the public summary
6.1 The PBAC recommended the listing of the new form of triglycerides, medium chain – oral liquid 225 mL, 15 (K.Quik®) to replace the PBS-listed Betaquik®.PSD · Mar 2022
6.2 The PBAC had no objection to the sponsor-initiated de-listing request of Betaquik.PSD · Mar 2022
5.1 The Nutritional Products Working Party (NPWP) supported the listing of a new brand K.Quik to replace the currently listed Betaquik brand.PSD · Mar 2022
Cost-effectiveness
Not modelled; this is a cost-neutral brand replacement with identical nutritional content to the existing PBS-listed Betaquik.
Decision context
PopulationPatients requiring a ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency; patients with chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, or fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2022 | Recommended | Betaquik | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to specific medical conditions (intractable seizures, metabolic disorders, fat malabsorption causes) within the broad TGA special medical purposes category.